The Clinical Study on the Treatment of SSc With UTAA91 Injection.

This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.

NCT Number	NCT07000682
Lead Sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions	Systemic Sclerosis (SSc)
Enrollment	24 participants
Start Date	2025-05-30
Primary Completion	2027-12 (estimated)
Study Completion	2040-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-18